Zhejiang Medicine Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Zhejiang Medicine kazanç ve gelirin sırasıyla yıllık 15.2% ve 9.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 15.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 11.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

15.2%

Kazanç büyüme oranı

15.1%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.7%
Gelir büyüme oranı	9.5%
Gelecekteki özkaynak getirisi	11.5%
Analist kapsamı	Low
Son güncelleme	29 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch

Nov 22

We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings

Nov 01

Is Zhejiang Medicine (SHSE:600216) A Risky Investment?

Sep 14

What Zhejiang Medicine Co., Ltd.'s (SHSE:600216) 27% Share Price Gain Is Not Telling You

Aug 06

Zhejiang Medicine (SHSE:600216) Is Reducing Its Dividend To CN¥0.15

Jul 05

The Market Doesn't Like What It Sees From Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Earnings Yet

Jun 21

Zhejiang Medicine's (SHSE:600216) Earnings Are Weaker Than They Seem

May 02

Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet

Mar 29

Kazanç ve Gelir Büyüme Tahminleri

SHSE:600216 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	11,373	1,549	N/A	1,246	2
12/31/2025	10,638	1,462	N/A	1,538	3
12/31/2024	9,820	1,388	N/A	1,026	3
9/30/2024	9,030	978	283	916	N/A
6/30/2024	8,262	473	-66	591	N/A
3/31/2024	8,035	426	-109	638	N/A
12/31/2023	7,794	430	-163	634	N/A
9/30/2023	7,868	356	-127	790	N/A
6/30/2023	7,936	421	-121	781	N/A
3/31/2023	7,940	393	-134	718	N/A
12/31/2022	8,116	540	-455	521	N/A
9/30/2022	8,441	779	-115	825	N/A
6/30/2022	8,629	928	-320	670	N/A
3/31/2022	8,913	1,039	-186	919	N/A
12/31/2021	9,129	1,045	197	1,137	N/A
9/30/2021	8,709	847	105	965	N/A
6/30/2021	8,416	798	402	1,209	N/A
3/31/2021	8,127	836	522	1,123	N/A
12/31/2020	7,327	717	721	1,257	N/A
9/30/2020	7,154	603	201	853	N/A
6/30/2020	6,987	489	234	782	N/A
3/31/2020	6,925	358	67	657	N/A
12/31/2019	7,044	343	-126	447	N/A
9/30/2019	7,073	210	116	496	N/A
6/30/2019	7,052	177	111	555	N/A
3/31/2019	6,655	32	288	693	N/A
12/31/2018	6,859	365	141	580	N/A
9/30/2018	6,879	636	225	652	N/A
6/30/2018	6,600	632	N/A	504	N/A
3/31/2018	6,426	694	N/A	335	N/A
12/31/2017	5,693	253	N/A	503	N/A
9/30/2017	5,224	176	N/A	375	N/A
6/30/2017	5,122	348	N/A	455	N/A
3/31/2017	5,159	409	N/A	535	N/A
12/31/2016	5,279	450	N/A	336	N/A
9/30/2016	5,089	378	N/A	381	N/A
6/30/2016	4,994	219	N/A	210	N/A
3/31/2016	4,757	255	N/A	17	N/A
12/31/2015	4,497	162	N/A	107	N/A
9/30/2015	4,505	62	N/A	253	N/A
6/30/2015	4,434	93	N/A	391	N/A
3/31/2015	4,644	47	N/A	475	N/A
12/31/2014	4,832	170	N/A	550	N/A
9/30/2014	4,843	326	N/A	595	N/A
6/30/2014	4,860	306	N/A	539	N/A
3/31/2014	4,887	365	N/A	597	N/A
12/31/2013	4,933	452	N/A	655	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 600216 'nin tahmini kazanç büyümesi (yıllık 15.2% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 600216 şirketinin kazançlarının (yıllık 15.2% ) CN pazarından (yıllık 26.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 600216 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 600216 şirketinin gelirinin (yıllık 9.5% ) CN pazarından (yıllık 13.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 600216 şirketinin gelirinin (yıllık 9.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 600216 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 11.5 %).

Zhejiang Medicine Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 35%

Consensus EPS estimates increase by 118%

Consensus EPS estimates fall by 14%

Price target decreased to CN¥16.03

Consensus EPS estimates fall by 11%

Price target raised to CN¥25.75

Recent updates

Zhejiang Medicine Co., Ltd. (SHSE:600216) Screens Well But There Might Be A Catch

We Think That There Are Issues Underlying Zhejiang Medicine's (SHSE:600216) Earnings

Consensus EPS estimates increase by 35%

Third quarter 2024 earnings released: EPS: CN¥0.55 (vs CN¥0.029 in 3Q 2023)

Investor sentiment improves as stock rises 20%

Zhejiang Medicine Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Is Zhejiang Medicine (SHSE:600216) A Risky Investment?

Consensus EPS estimates increase by 118%

Second quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.16 in 2Q 2023)

New minor risk - Share price stability

What Zhejiang Medicine Co., Ltd.'s (SHSE:600216) 27% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 19%

Zhejiang Medicine (SHSE:600216) Is Reducing Its Dividend To CN¥0.15

Dividend reduced to CN¥0.15

Zhejiang Medicine Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

The Market Doesn't Like What It Sees From Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Earnings Yet

Zhejiang Medicine Co., Ltd., Annual General Meeting, Jun 18, 2024

Zhejiang Medicine's (SHSE:600216) Earnings Are Weaker Than They Seem

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 1Q 2023)

Zhejiang Medicine Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Zhejiang Medicine (SHSE:600216) Has A Somewhat Strained Balance Sheet

Investor sentiment improves as stock rises 18%

Zhejiang Medicine Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.029 (vs CN¥0.10 in 3Q 2022)

Zhejiang Medicine Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Consensus EPS estimates fall by 14%

Second quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 2Q 2022)

Zhejiang Medicine Co., Ltd. to Report First Half, 2023 Results on Aug 24, 2023

First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.27 in 1Q 2022)

Price target decreased to CN¥16.03

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.25 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.25 in 2Q 2021)

Consensus EPS estimates fall by 11%

First quarter 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.20 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.30 in 2Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.75 (vs CN¥0.36 in FY 2019)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥12.75

New 90-day low: CN¥13.19

Price target raised to CN¥25.75

Third quarter earnings released

New 90-day low: CN¥14.55

Third quarter earnings released

Zhejiang Medicine Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low: CN¥15.44

New 90-day low - CN¥16.73

First half earnings released

Earnings released

Zhejiang Medicine Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin